RPC1063: Phase II/III ongoing

According to an S-1 filed by Receptos on Dec. 24, 2013, Receptos began the Phase III portion of the Phase II/III RADIANCE trial to compare 0.5 and 1 mg RPC1063 vs. interferon beta-1a in about 1,200 relapsing MS patients. In early December, DMC recommended continuing the Phase II portion and starting the Phase III portion of the RADIANCE trial based on an interim analysis (see BioCentury, Dec. 9, 2013). ...